This database contains 1058 studies, archived under the term: "aged"
Click here to filter this large number of results.
Effect of Active Music Therapy and Individualized Listening to Music on Dementia: A Multicenter Randomized Controlled Trial
Raglio, A.,
Bellandi, D.,
Baiardi, P.,
Gianotti, M.,
Ubezio, M.C.,
Zanacchi, E.,
Granieri, E.,
Imbriani, M.,
Stramba-Badiale, M.
OBJECTIVES: To assess the effects of active music therapy (MT) and individualized listening to music (LtM) on behavioral and psychological symptoms of dementia (BPSDs) in persons with dementia (PWDs). DESIGN: Randomized controlled trial. SETTING: Nine Italian institutions. PARTICIPANTS: Persons with moderate to severe dementia and BPSDs (N = 120) were randomized to one of three […]
Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study
Sarkamo, T.,
Tervaniemi, M.,
Laitinen, S.,
Numminen, A.,
Kurki, M.,
Johnson, J. K.,
Rantanen, P.
PURPOSE OF THE STUDY: During aging, musical activities can help maintain physical and mental health and cognitive abilities, but their rehabilitative use has not been systematically explored in persons with dementia (PWDs). Our aim was to determine the efficacy of a novel music intervention based on coaching the caregivers of PWDs to use either singing […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes
Nakagawa, Kiyotaka,
Kiko, Takehiro,
Miyazawa, Taiki,
Carpentero Burdeos, Gregor,
Kimura, Fumiko,
Satoh, Akira,
Miyazawa, Teruo
Phospholipid hydroperoxides (PLOOH) accumulate abnormally in the erythrocytes of dementia patients, and dietary xanthophylls (polar carotenoids such as astaxanthin) are hypothesised to prevent the accumulation. In the present study, we conducted a randomised, double-blind, placebo-controlled human trial to assess the efficacy of 12-week astaxanthin supplementation (6 or 12 mg/d) on both astaxanthin and PLOOH levels in […]
Extended results of the Alzheimer’s disease anti-inflammatory prevention trial
Breitner, John C.,
Baker, Laura D.,
Montine, Thomas J.,
Meinert, Curtis L.,
Lyketsos, Constantine G.,
Ashe, Karen H.,
Brandt, Jason,
Craft, Suzanne,
Evans, Denis E.,
Green, Robert C.,
Ismail, M. Saleem,
Martin, Barbara K.,
Mullan, Michael J.,
Sabbagh, Marwan,
Tariot, Pierre N.
Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments […]
Methodological issues in a cluster-randomized trial to prevent dementia by intensive vascular care
Objectives: Description of methodological issues in a trial designed to evaluate if a multi-component intervention aimed at vascular risk factors can prevent dementia.; Design, Setting and Participants: Multi-center, open, cluster-randomized controlled clinical trial (preDIVA) including 3535 non-demented subjects aged 70-78, executed in primary practice and coordinated from one academic hospital. General practices are randomized to […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]